Clinical trialNCT00794144CompletedPhase 2Interventional

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

SponsorAlcon ResearchEnrollment132Allergic Rhinitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug in the body) in these children

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Albert Finn, MD
National Allergy, Asthma, & Urticaria
Principal Investigator
clinicaltrials.gov ↗
Brad H Goodman, MD
Aeroallergy Research Laboratories
Principal Investigator
clinicaltrials.gov ↗
Christopher Smith, MD
Asthma and Allergy Associates, P.C.
Principal Investigator
clinicaltrials.gov ↗
Frank Hampel, MD
Central Texas Allergy and Asthma
Principal Investigator
clinicaltrials.gov ↗
John Prestigiacomo, MD
Gulf Coast Research Associates, Inc
Principal Investigator
clinicaltrials.gov ↗
Joseph Flanagan, MD
Health Sciences Research Center
Principal Investigator
clinicaltrials.gov ↗
Neil Kao, MD
Allergic Disease and Asthma Cente
Principal Investigator
clinicaltrials.gov ↗
Niran Amar, MD
Principal Investigator
clinicaltrials.gov ↗
Paul Ratner, MD
Sylvana Research Associates
Principal Investigator
clinicaltrials.gov ↗
Sheri Byrd, MD
Spartanburg Medical Center
Principal Investigator
clinicaltrials.gov ↗
Yu-Luen Hsu, MD
West Coast Clinical Trials Phase 2-4
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Niran Amar, M.D.
Waco, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Olopatadine Hydrochloride Nasal Spray 0.6%Olopatadine Hydrochloride Nasal Spray Vehicle

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2008
Primary completion: 31 Dec 2008
Completion: —
Last update posted: 4 Mar 2010
Registered enrollment: 132
Registry id: NCT00794144

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.